Nevertheless, regardless of the presence of the tumor, both VSV-GP-OVA treatment groups showed a significantly increased SLEC proportion among OVA-specific CD8+ T cells after the boost compared to the prime immunization. The gene discussed is CD8A; the disease is neoplasm.